Literature DB >> 29739059

LncRNA PVT1: a Novel Therapeutic Target for Cancers.

Xuefeng Pan, Guobao Zheng, Chunfang Gao.   

Abstract

BACKGROUND: Long non-coding RNA PVT1, as an important carcinogenic lncRNA, is highly expressed in many malignant tumors and suggests a poorer prognosis. It can promote the occurrence and development of cancers by affecting cell proliferation, migration, invasion and apoptosis. This article reviews the progress of lncRNA PVT1 on cancer therapy, in order to facilitate the in-depth study of lncRNA PVT1 acting as a promising target for therapy in cancers.
METHODS: We extracted all relevant studies of lncRNA PVT1 on the treatment of cancers by searching electronic databases Pubmed, Embase, Web of Science from inception to November 30, 2017.
RESULTS: Accumulating vigorous evidence has shown that lncRNA PVT1 performs a significant carcinogenic activity in various cancers, for instance, negatively modulating miRNA as a ceRNA or a molecular sponge to exert tumor-promoting effect. Based on the critical role of lncRNA PVT1 in the pathogenesis of cancers, numerous studies have already demonstrated that lncRNA PVT1 might serve as a potential therapeutic target for various cancers, such as non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, breast cancer, glioma, etc.
CONCLUSIONS: Numerous studies have indicated that lncRNA PVT1 will most likely become a novel target for cancer therapy with the deepening systematic research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739059     DOI: 10.7754/Clin.Lab.2018.171216

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  15 in total

1.  Downregulating lncRNA PVT1 Relieves Astrocyte Overactivation Induced Neuropathic Pain Through Targeting miR-186-5p/CXCL13/CXCR5 Axis.

Authors:  Peisong Zhang; Hanyu Sun; Zhengang Ji
Journal:  Neurochem Res       Date:  2021-03-19       Impact factor: 3.996

Review 2.  Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty.

Authors:  Cedric Badowski; Bing He; Lana X Garmire
Journal:  NPJ Precis Oncol       Date:  2022-06-21

3.  Retracted Article: PVT1 knockdown alleviates vancomycin-induced acute kidney injury by targeting miR-124 via inactivation of NF-κB signaling.

Authors:  Xiaoguang Zhu; Jun Shi; Huicong Li; Fang Chen
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036

Review 4.  Long Non-coding RNA HOTAIR in Central Nervous System Disorders: New Insights in Pathogenesis, Diagnosis, and Therapeutic Potential.

Authors:  Jialu Wang; Jiuhan Zhao; Pan Hu; Lianbo Gao; Shen Tian; Zhenwei He
Journal:  Front Mol Neurosci       Date:  2022-06-23       Impact factor: 6.261

5.  The lncRNA PVT1 promotes invasive growth of lung adenocarcinoma cells by targeting miR-378c to regulate SLC2A1 expression.

Authors:  Hongwei Xia; Zhiqiang Zhang; Jun Yuan; Qingling Niu
Journal:  Hum Cell       Date:  2020-09-22       Impact factor: 4.174

Review 6.  Biomarkers in Colorectal Cancer: Current Research and Future Prospects.

Authors:  Olorunseun O Ogunwobi; Fahad Mahmood; Akinfemi Akingboye
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

Review 7.  Epitranscriptomic Signatures in lncRNAs and Their Possible Roles in Cancer.

Authors:  Sorina Dinescu; Simona Ignat; Andreea Daniela Lazar; Carolina Constantin; Monica Neagu; Marieta Costache
Journal:  Genes (Basel)       Date:  2019-01-16       Impact factor: 4.096

8.  A five-long non-coding RNA signature with the ability to predict overall survival of patients with lung adenocarcinoma.

Authors:  Lizhong Zeng; Wei Wang; Yang Chen; Xin Lv; Jingyan Yuan; Ruiying Sun; Shuanying Yang
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

9.  Robust analysis of novel mRNA-lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer.

Authors:  Li-Ping Chen; Hong Wang; Yi Zhang; Qiu-Xiang Chen; Tie-Su Lin; Zong-Qin Liu; Yang-Yang Zhou
Journal:  Cancer Manag Res       Date:  2018-12-27       Impact factor: 3.989

10.  Long noncoding RNA VPS9D1-AS1 augments the malignant phenotype of non-small cell lung cancer by sponging microRNA-532-3p and thereby enhancing HMGA2 expression.

Authors:  Xiao Han; Tianren Huang; Junqing Han
Journal:  Aging (Albany NY)       Date:  2020-01-05       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.